Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Lung cancer is the leading cause of cancer-related death worldwide. The development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) has brought favorable survival benefits to patients with non–small-cell lung cancer (NSCLC); unfortun...

Full description

Bibliographic Details
Main Authors: Dai Cao, Die Chen, Jiang-Nan Xia, Wen-Yan Wang, Guo-Yuan Zhu, Li-Wen Chen, Chuantao Zhang, Bo Tan, Hui Li, Ying-Wei Li
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Anti-tumor immunity
Artesunate
EGFR-TKI resistance
Non-small-cell lung cancer
PD-L1
TAZ
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222010940

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222010940

Similar Items